Response-guided telaprevir combination treatment for hepatitis C virus infection.

Telaprevir for previously untreated chronic hepatitis C virus infection

Jacobson I. M.
McHutchison J. G.
Dusheiko G.
Di Bisceglie A. M.
Reddy K. R.
Bzowej N. H.
Marcellin P.
Muir A. J.
Ferenci P.
Flisiak R.
George J.
Rizzetto M.
Shouval D.
Sola R.
Terg R. A.
Yoshida E. M.
Adda N.
Bengtsson L.
Sankoh A. J.
Kieffer T. L.
George S.
Kauffman R. S.
Zeuzem S.
ADVANCE Study Team: Gadano A.
Terg R.
Bell S.
Cheng W.
Crawford D.
Dore G.
George J.
MacDonald G.
Roberts S.
Ferenci P.
Gschwantler M.
Laferl H.
Maieron A.
Heathcote J.
Kaita K.
Myers R.
Sherman M.
Yoshida E.
Barange K.
Couzigou P.
Marcellin P.
Pawlotsky J. M.
Pol S.
Serfaty L.
Trépo C.
Zarski J. P.
Berg T.
Buggisch P.
Diepolder H.
Goeser T.
Mauss S.
Rasenack J.
Schmidt W.
Wedemeyer H.
Zeuzem S.
Baruch Y.
Ben Ari Z.
Maor Y.
Safadi R.
Shouval D.
Zuckerman E.
ANDREONE, PIETRO
Colombo M.
Rizzetto M.
Baka Cwierz B.
Flisiak R.
Gladysz A.
Janczewska Kazek E.
Jablkowski M.
Krycka W.
Diago M.
Esteban Mur R.
Sanchez Tapias J.
Sola R.
Brown A.
Dusheiko G.
Fox R.
Afdhal N.
Arora S.
Bennett M.
Bernstein D.
Bloomer J.
Bochan M.
Bonkovsky H.
Brady C.
Brown R.
Bzowej N.
Cochran J.
Chasen R.
Davis G.
De Jesus E.
Di Bisceglie A.
Dienstag J.
Dieterich D.
Etzkorn K.
Everson G.
Fried M.
Freilich B.
Ghalib R.
Gitlin N.
Godofsky E.
Gordon S.
Hassanein T.
Jacobson I.
Javadi F.
Jonas M.
Kilby A.
Kwo P.
Lawitz E.
Lebovics E.
Lee W.
Luketic V.
Maillard M.
Monto A.
Morgan T.
Min A.
Murphy M.
Nelson D.
Northup P.
Nyberg L.
Pockros P.
Poordad F.
Poulos J.
Reddy R.
Rodriguez Torres M.
Satyanarayana R.
Schiff E.
Schwartz H.
Shaikh O.
Sheikh M.
Sherman K.
Smith J.
Strohecker J.
Sulkowski M.
Szabo G.
Te H.
Terrault N.
Tsai N.
Vargas H.
Vierling J.
Wruble L.
Younossi Z.
Zein N.

January 2011

BACKGROUND: In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, ...

Telaprevir for previously untreated chronic hepatitis C virus infection.

Jacobson I. M.
McHutchison J. G.
Dusheiko G.
Di Bisceglie A. M.
Reddy K. R.
Bzowej N. H.
Marcellin P.
Muir A. J.
Ferenci P.
Flisiak R.
George J.
Rizzetto M.
Shouval D.
Sola R.
Terg R. A.
Yoshida E. M.
Adda N.
Bengtsson L.
Sankoh A. J.
Kieffer T. L.
George S.
Kauffman R. S.
Zeuzem S.
ADVANCE Study Team: Gadano A.
Terg R.
Bell S.
Cheng W.
Crawford D.
Dore G.
George J.
MacDonald G.
Roberts S.
Ferenci P.
Gschwantler M.
Laferl H.
Maieron A.
Heathcote J.
Kaita K.
Myers R.
Sherman M.
Yoshida E.
Barange K.
Couzigou P.
Marcellin P.
Pawlotsky J. M.
Pol S.
Serfaty L.
Trépo C.
Zarski J. P.
Berg T.
Buggisch P.
Diepolder H.
Goeser T.
Mauss S.
Rasenack J.
Schmidt W.
Wedemeyer H.
Zeuzem S.
Baruch Y.
Ben Ari Z.
Maor Y.
Safadi R.
Shouval D.
Zuckerman E.
Colombo M.
Rizzetto M.
Baka Cwierz B.
Flisiak R.
Gladysz A.
Janczewska Kazek E.
Jablkowski M.
Krycka W.
Diago M.
Esteban Mur R.
Sanchez Tapias J.
Sola R.
Brown A.
Dusheiko G.
Fox R.
Afdhal N.
Arora S.
Bennett M.
Bernstein D.
Bloomer J.
Bochan M.
Bonkovsky H.
Brady C.
Brown R.
Bzowej N.
Cochran J.
Chasen R.
Davis G.
De Jesus E.
Di Bisceglie A.
Dienstag J.
Dieterich D.
Etzkorn K.
Everson G.
Fried M.
Freilich B.
Ghalib R.
Gitlin N.
Godofsky E.
Gordon S.
Hassanein T.
Jacobson I.
Javadi F.
Jonas M.
Kilby A.
Kwo P.
Lawitz E.
Lebovics E.
Lee W.
Luketic V.
Maillard M.
Monto A.
Morgan T.
Min A.
Murphy M.
Nelson D.
Northup P.
Nyberg L.
Pockros P.
Poordad F.
Poulos J.
Reddy R.
Rodriguez Torres M.
Satyanarayana R.
Schiff E.
Schwartz H.
Shaikh O.
Sheikh M.
Sherman K.
Smith J.
Strohecker J.
Sulkowski M.
Szabo G.
Te H.
Terrault N.
Tsai N.
Vargas H.
Vierling J.
Wruble L.
Younossi Z.
Zein N.
ANDREONE, PIETRO

January 2011

BACKGROUND: In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, ...

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.

Muir, Andrew,
Poordad, Fred,
Mchutchison, John,
Shiffman, Mitchell,
Berg, Thomas
Ferenci, Peter
Heathcote, E Jenny
Pawlotsky, Jean-Michel
Zeuzem, Stefan
Reesink, Henk,
Dusheiko, Geoffrey
Martin, Emily,
George, Shelley
Kauffman, Robert,
Adda, Nathalie

November 2011

International audienceRetreatment with peginterferon alpha and ribavirin (PR) offers a limited chanc...

Response-guided telaprevir combination treatment for hepatitis C virus infection

Sherman, Kenneth K.E.
Flamm, Steven S.L.
Afdhal, Nezam N.H.
Nelson, David
Sulkowski, Mark
Everson, Gregory G.T.
Fried, Michael
Adler, Michael
Reesink, Hendrik
Martin, Marie
Sankoh, Abdul A.J.
Adda, Nathalie
Kauffman, Robert R.S.
George, Shelley
Wright, Christopher C.I.
Poordad, Fred

September 2011

BACKGROUND: Patients with chronic infection with hepatitis C virus (HCV) genotype 1 often need 48 we...

TELAPREVIR COMBINATION RESPONSE-GUIDED HEPATITIS C INFECTION MANAGEMENT

Dr Aiman Maghfoor, Dr. Shifa Sajjad, Dr Huda Iftikhar

September 2020

Aim: Patients with interminable disease with hepatitis C infection genotype 1 frequently need 48 wee...

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

Sherman, Kenneth E.
Flamm, Steven L.
Afdhal, Nezam H.
Nelson, David R.
Sulkowski, Mark S.
Everson, Gregory T.
Fried, Michael W.
Adler, Michael
Reesink, Hendrik W.
Martin, Marie
Sankoh, Abdul J.
Adda, Nathalie
Kauffman, Robert S.
George, Shelley
Wright, Christopher I.
Poordad, Fred

January 2011

Patients with chronic infection with hepatitis C virus (HCV) genotype 1 often need 48 weeks of pegin...

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

Sherman, Kenneth E.
Flamm, Steven L.
Afdhal, Nezam H.
Nelson, David R.
Sulkowski, Mark S.
Everson, Gregory T.
Fried, Michael W.
Adler, Michael
Reesink, Hendrik W.
Martin, Marie
Sankoh, Abdul J.
Adda, Nathalie
Kauffman, Robert S.
George, Shelley
Wright, Christopher I.
Poordad, Fred

January 2011

Patients with chronic infection with hepatitis C virus (HCV) genotype 1 often need 48 weeks of pegin...

Telaprevir for retreatment of HCV infection.

Zeuzem, S.
Andreone, P.
Pol, S. van der
Lawitz, E.
Diago, M.
Roberts, S.
Focaccia, R.
Younossi, Z.
Foster, G.R.
Horban, A.
Ferenci, P.
Nevens, F.
Mullhaupt, B.
Pockros, P.
Terg, R.
Shouval, D.
Hoek, B. van
Weiland, O.
Heeswijk, R. Van
Meyer, S.
Luo, D.
Boogaerts, G.
Polo, R.
Picchio, G.
Beumont, M.
Drenth, J.P.H.
et al.

January 2011

BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a su...

Telaprevir for retreatment of HCV infection

Zeuzem S
Pol S
Lawitz E
Diago M
Roberts S
Focaccia R
Younossi Z
Foster GR
Horban A
Ferenci P
Nevens F
Müllhaupt B
Pockros P
Terg R
Shouval D
van Hoek B
Weiland O
Van Heeswijk R
De Meyer S
Luo D
Boogaerts G
Polo R
Picchio G
Beumont M
REALIZE Study Team
ANDREONE, PIETRO

January 2011

BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a su...

Tailoring response-based treatment for hepatitis C

Ho, Antonia
Fox, Ray

February 2011

The recommended treatment for chronic infection with hepatitis C virus (HCV) is a combination of peg...

Telaprevir for retreatment of HCV infection

Zeuzem S
Andreone P
Pol S
Lawitz E
Diago M
Roberts S
Focaccia R
Younossi Z
Foster GR
Horban A
Ferenci P
Nevens F
Müllhaupt B
Pockros P
Terg R
Shouval D
van Hoek B
Weiland O
Van Heeswijk R
De Meyer S
Luo D
Boogaerts G
Polo R
Picchio G
Beumont M
REALIZE Study Team.

January 2011

BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a su...

Telaprevir for retreatment of HCV infection

Zeuzem S
Andreone P
Pol S
Lawitz E
Diago M
Roberts S
Focaccia R
Younossi Z
Foster GR
Horban A
Ferenci P
Nevens F
Müllhaupt B
Pockros P
Terg R
Shouval D
van Hoek B
Weiland O
Van Heeswijk R
De Meyer S
Luo D
Boogaerts G
Polo R
Picchio G
Beumont M
REALIZE Study Team.

January 2011

BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a su...

Telaprevir for retreatment of HCV infection

Zeuzem S
Pol S
Lawitz E
Diago M
Roberts S
Focaccia R
Younossi Z
Foster GR
Horban A
Ferenci P
Nevens F
Müllhaupt B
Pockros P
Terg R
Shouval D
van Hoek B
Weiland O
Van Heeswijk R
De Meyer S
Luo D
Boogaerts G
Polo R
Picchio G
Beumont M
REALIZE Study Team
ANDREONE, PIETRO

January 2011

BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a su...

Telaprevir for retreatment of HCV infection

Zeuzem S
Andreone P
Pol S
Lawitz E
Diago M
Roberts S
Focaccia R
Younossi Z
Foster GR
Horban A
Ferenci P
Nevens F
Müllhaupt B
Pockros P
Terg R
Shouval D
van Hoek B
Weiland O
Van Heeswijk R
De Meyer S
Luo D
Boogaerts G
Polo R
Picchio G
Beumont M
REALIZE Study Team.

January 2011

BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a su...

Tailoring response-based treatment for hepatitis C

Ho, Antonia
Fox, Ray

February 2011

The recommended treatment for chronic infection with hepatitis C virus (HCV) is a combination of peg...

Telaprevir for previously untreated chronic hepatitis C virus infection

Jacobson I. M.
McHutchison J. G.
Dusheiko G.
Di Bisceglie A. M.
Reddy K. R.
Bzowej N. H.
Marcellin P.
Muir A. J.
Ferenci P.
Flisiak R.
George J.
Rizzetto M.
Shouval D.
Sola R.
Terg R. A.
Yoshida E. M.
Adda N.
Bengtsson L.
Sankoh A. J.
Kieffer T. L.
George S.
Kauffman R. S.
Zeuzem S.
ADVANCE Study Team: Gadano A.
Terg R.
Bell S.
Cheng W.
Crawford D.
Dore G.
George J.
MacDonald G.
Roberts S.
Ferenci P.
Gschwantler M.
Laferl H.
Maieron A.
Heathcote J.
Kaita K.
Myers R.
Sherman M.
Yoshida E.
Barange K.
Couzigou P.
Marcellin P.
Pawlotsky J. M.
Pol S.
Serfaty L.
Trépo C.
Zarski J. P.
Berg T.
Buggisch P.
Diepolder H.
Goeser T.
Mauss S.
Rasenack J.
Schmidt W.
Wedemeyer H.
Zeuzem S.
Baruch Y.
Ben Ari Z.
Maor Y.
Safadi R.
Shouval D.
Zuckerman E.
ANDREONE, PIETRO
Colombo M.
Rizzetto M.
Baka Cwierz B.
Flisiak R.
Gladysz A.
Janczewska Kazek E.
Jablkowski M.
Krycka W.
Diago M.
Esteban Mur R.
Sanchez Tapias J.
Sola R.
Brown A.
Dusheiko G.
Fox R.
Afdhal N.
Arora S.
Bennett M.
Bernstein D.
Bloomer J.
Bochan M.
Bonkovsky H.
Brady C.
Brown R.
Bzowej N.
Cochran J.
Chasen R.
Davis G.
De Jesus E.
Di Bisceglie A.
Dienstag J.
Dieterich D.
Etzkorn K.
Everson G.
Fried M.
Freilich B.
Ghalib R.
Gitlin N.
Godofsky E.
Gordon S.
Hassanein T.
Jacobson I.
Javadi F.
Jonas M.
Kilby A.
Kwo P.
Lawitz E.
Lebovics E.
Lee W.
Luketic V.
Maillard M.
Monto A.
Morgan T.
Min A.
Murphy M.
Nelson D.
Northup P.
Nyberg L.
Pockros P.
Poordad F.
Poulos J.
Reddy R.
Rodriguez Torres M.
Satyanarayana R.
Schiff E.
Schwartz H.
Shaikh O.
Sheikh M.
Sherman K.
Smith J.
Strohecker J.
Sulkowski M.
Szabo G.
Te H.
Terrault N.
Tsai N.
Vargas H.
Vierling J.
Wruble L.
Younossi Z.
Zein N.

January 2011

BACKGROUND: In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, ...

Telaprevir for previously untreated chronic hepatitis C virus infection.

Jacobson I. M.
McHutchison J. G.
Dusheiko G.
Di Bisceglie A. M.
Reddy K. R.
Bzowej N. H.
Marcellin P.
Muir A. J.
Ferenci P.
Flisiak R.
George J.
Rizzetto M.
Shouval D.
Sola R.
Terg R. A.
Yoshida E. M.
Adda N.
Bengtsson L.
Sankoh A. J.
Kieffer T. L.
George S.
Kauffman R. S.
Zeuzem S.
ADVANCE Study Team: Gadano A.
Terg R.
Bell S.
Cheng W.
Crawford D.
Dore G.
George J.
MacDonald G.
Roberts S.
Ferenci P.
Gschwantler M.
Laferl H.
Maieron A.
Heathcote J.
Kaita K.
Myers R.
Sherman M.
Yoshida E.
Barange K.
Couzigou P.
Marcellin P.
Pawlotsky J. M.
Pol S.
Serfaty L.
Trépo C.
Zarski J. P.
Berg T.
Buggisch P.
Diepolder H.
Goeser T.
Mauss S.
Rasenack J.
Schmidt W.
Wedemeyer H.
Zeuzem S.
Baruch Y.
Ben Ari Z.
Maor Y.
Safadi R.
Shouval D.
Zuckerman E.
Colombo M.
Rizzetto M.
Baka Cwierz B.
Flisiak R.
Gladysz A.
Janczewska Kazek E.
Jablkowski M.
Krycka W.
Diago M.
Esteban Mur R.
Sanchez Tapias J.
Sola R.
Brown A.
Dusheiko G.
Fox R.
Afdhal N.
Arora S.
Bennett M.
Bernstein D.
Bloomer J.
Bochan M.
Bonkovsky H.
Brady C.
Brown R.
Bzowej N.
Cochran J.
Chasen R.
Davis G.
De Jesus E.
Di Bisceglie A.
Dienstag J.
Dieterich D.
Etzkorn K.
Everson G.
Fried M.
Freilich B.
Ghalib R.
Gitlin N.
Godofsky E.
Gordon S.
Hassanein T.
Jacobson I.
Javadi F.
Jonas M.
Kilby A.
Kwo P.
Lawitz E.
Lebovics E.
Lee W.
Luketic V.
Maillard M.
Monto A.
Morgan T.
Min A.
Murphy M.
Nelson D.
Northup P.
Nyberg L.
Pockros P.
Poordad F.
Poulos J.
Reddy R.
Rodriguez Torres M.
Satyanarayana R.
Schiff E.
Schwartz H.
Shaikh O.
Sheikh M.
Sherman K.
Smith J.
Strohecker J.
Sulkowski M.
Szabo G.
Te H.
Terrault N.
Tsai N.
Vargas H.
Vierling J.
Wruble L.
Younossi Z.
Zein N.
ANDREONE, PIETRO

January 2011

BACKGROUND: In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, ...

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.

Muir, Andrew,
Poordad, Fred,
Mchutchison, John,
Shiffman, Mitchell,
Berg, Thomas
Ferenci, Peter
Heathcote, E Jenny
Pawlotsky, Jean-Michel
Zeuzem, Stefan
Reesink, Henk,
Dusheiko, Geoffrey
Martin, Emily,
George, Shelley
Kauffman, Robert,
Adda, Nathalie

November 2011

International audienceRetreatment with peginterferon alpha and ribavirin (PR) offers a limited chanc...

Response-guided telaprevir combination treatment for hepatitis C virus infection

Sherman, Kenneth K.E.
Flamm, Steven S.L.
Afdhal, Nezam N.H.
Nelson, David
Sulkowski, Mark
Everson, Gregory G.T.
Fried, Michael
Adler, Michael
Reesink, Hendrik
Martin, Marie
Sankoh, Abdul A.J.
Adda, Nathalie
Kauffman, Robert R.S.
George, Shelley
Wright, Christopher C.I.
Poordad, Fred

September 2011

BACKGROUND: Patients with chronic infection with hepatitis C virus (HCV) genotype 1 often need 48 we...

TELAPREVIR COMBINATION RESPONSE-GUIDED HEPATITIS C INFECTION MANAGEMENT

Dr Aiman Maghfoor, Dr. Shifa Sajjad, Dr Huda Iftikhar

September 2020

Aim: Patients with interminable disease with hepatitis C infection genotype 1 frequently need 48 wee...

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

Sherman, Kenneth E.
Flamm, Steven L.
Afdhal, Nezam H.
Nelson, David R.
Sulkowski, Mark S.
Everson, Gregory T.
Fried, Michael W.
Adler, Michael
Reesink, Hendrik W.
Martin, Marie
Sankoh, Abdul J.
Adda, Nathalie
Kauffman, Robert S.
George, Shelley
Wright, Christopher I.
Poordad, Fred

January 2011

Patients with chronic infection with hepatitis C virus (HCV) genotype 1 often need 48 weeks of pegin...

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

Sherman, Kenneth E.
Flamm, Steven L.
Afdhal, Nezam H.
Nelson, David R.
Sulkowski, Mark S.
Everson, Gregory T.
Fried, Michael W.
Adler, Michael
Reesink, Hendrik W.
Martin, Marie
Sankoh, Abdul J.
Adda, Nathalie
Kauffman, Robert S.
George, Shelley
Wright, Christopher I.
Poordad, Fred

January 2011

Patients with chronic infection with hepatitis C virus (HCV) genotype 1 often need 48 weeks of pegin...

Telaprevir for retreatment of HCV infection.

Zeuzem, S.
Andreone, P.
Pol, S. van der
Lawitz, E.
Diago, M.
Roberts, S.
Focaccia, R.
Younossi, Z.
Foster, G.R.
Horban, A.
Ferenci, P.
Nevens, F.
Mullhaupt, B.
Pockros, P.
Terg, R.
Shouval, D.
Hoek, B. van
Weiland, O.
Heeswijk, R. Van
Meyer, S.
Luo, D.
Boogaerts, G.
Polo, R.
Picchio, G.
Beumont, M.
Drenth, J.P.H.
et al.

January 2011

BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a su...

Telaprevir for retreatment of HCV infection

Zeuzem S
Pol S
Lawitz E
Diago M
Roberts S
Focaccia R
Younossi Z
Foster GR
Horban A
Ferenci P
Nevens F
Müllhaupt B
Pockros P
Terg R
Shouval D
van Hoek B
Weiland O
Van Heeswijk R
De Meyer S
Luo D
Boogaerts G
Polo R
Picchio G
Beumont M
REALIZE Study Team
ANDREONE, PIETRO

January 2011

BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a su...

Tailoring response-based treatment for hepatitis C

Ho, Antonia
Fox, Ray

February 2011

The recommended treatment for chronic infection with hepatitis C virus (HCV) is a combination of peg...

Telaprevir for retreatment of HCV infection

Zeuzem S
Andreone P
Pol S
Lawitz E
Diago M
Roberts S
Focaccia R
Younossi Z
Foster GR
Horban A
Ferenci P
Nevens F
Müllhaupt B
Pockros P
Terg R
Shouval D
van Hoek B
Weiland O
Van Heeswijk R
De Meyer S
Luo D
Boogaerts G
Polo R
Picchio G
Beumont M
REALIZE Study Team.

January 2011

BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a su...

Telaprevir for retreatment of HCV infection

Zeuzem S
Andreone P
Pol S
Lawitz E
Diago M
Roberts S
Focaccia R
Younossi Z
Foster GR
Horban A
Ferenci P
Nevens F
Müllhaupt B
Pockros P
Terg R
Shouval D
van Hoek B
Weiland O
Van Heeswijk R
De Meyer S
Luo D
Boogaerts G
Polo R
Picchio G
Beumont M
REALIZE Study Team.

January 2011

BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a su...

Telaprevir for retreatment of HCV infection

Zeuzem S
Pol S
Lawitz E
Diago M
Roberts S
Focaccia R
Younossi Z
Foster GR
Horban A
Ferenci P
Nevens F
Müllhaupt B
Pockros P
Terg R
Shouval D
van Hoek B
Weiland O
Van Heeswijk R
De Meyer S
Luo D
Boogaerts G
Polo R
Picchio G
Beumont M
REALIZE Study Team
ANDREONE, PIETRO

January 2011

BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a su...

Telaprevir for retreatment of HCV infection

Zeuzem S
Andreone P
Pol S
Lawitz E
Diago M
Roberts S
Focaccia R
Younossi Z
Foster GR
Horban A
Ferenci P
Nevens F
Müllhaupt B
Pockros P
Terg R
Shouval D
van Hoek B
Weiland O
Van Heeswijk R
De Meyer S
Luo D
Boogaerts G
Polo R
Picchio G
Beumont M
REALIZE Study Team.

January 2011

BACKGROUND: Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a su...

Tailoring response-based treatment for hepatitis C

Ho, Antonia
Fox, Ray

February 2011

The recommended treatment for chronic infection with hepatitis C virus (HCV) is a combination of peg...

Telaprevir for previously untreated chronic hepatitis C virus infection

Jacobson I. M.
McHutchison J. G.
Dusheiko G.
Di Bisceglie A. M.
Reddy K. R.
Bzowej N. H.
Marcellin P.
Muir A. J.
Ferenci P.
Flisiak R.
George J.
Rizzetto M.
Shouval D.
Sola R.
Terg R. A.
Yoshida E. M.
Adda N.
Bengtsson L.
Sankoh A. J.
Kieffer T. L.
George S.
Kauffman R. S.
Zeuzem S.
ADVANCE Study Team: Gadano A.
Terg R.
Bell S.
Cheng W.
Crawford D.
Dore G.
George J.
MacDonald G.
Roberts S.
Ferenci P.
Gschwantler M.
Laferl H.
Maieron A.
Heathcote J.
Kaita K.
Myers R.
Sherman M.
Yoshida E.
Barange K.
Couzigou P.
Marcellin P.
Pawlotsky J. M.
Pol S.
Serfaty L.
Trépo C.
Zarski J. P.
Berg T.
Buggisch P.
Diepolder H.
Goeser T.
Mauss S.
Rasenack J.
Schmidt W.
Wedemeyer H.
Zeuzem S.
Baruch Y.
Ben Ari Z.
Maor Y.
Safadi R.
Shouval D.
Zuckerman E.
ANDREONE, PIETRO
Colombo M.
Rizzetto M.
Baka Cwierz B.
Flisiak R.
Gladysz A.
Janczewska Kazek E.
Jablkowski M.
Krycka W.
Diago M.
Esteban Mur R.
Sanchez Tapias J.
Sola R.
Brown A.
Dusheiko G.
Fox R.
Afdhal N.
Arora S.
Bennett M.
Bernstein D.
Bloomer J.
Bochan M.
Bonkovsky H.
Brady C.
Brown R.
Bzowej N.
Cochran J.
Chasen R.
Davis G.
De Jesus E.
Di Bisceglie A.
Dienstag J.
Dieterich D.
Etzkorn K.
Everson G.
Fried M.
Freilich B.
Ghalib R.
Gitlin N.
Godofsky E.
Gordon S.
Hassanein T.
Jacobson I.
Javadi F.
Jonas M.
Kilby A.
Kwo P.
Lawitz E.
Lebovics E.
Lee W.
Luketic V.
Maillard M.
Monto A.
Morgan T.
Min A.
Murphy M.
Nelson D.
Northup P.
Nyberg L.
Pockros P.
Poordad F.
Poulos J.
Reddy R.
Rodriguez Torres M.
Satyanarayana R.
Schiff E.
Schwartz H.
Shaikh O.
Sheikh M.
Sherman K.
Smith J.
Strohecker J.
Sulkowski M.
Szabo G.
Te H.
Terrault N.
Tsai N.
Vargas H.
Vierling J.
Wruble L.
Younossi Z.
Zein N.

January 2011

BACKGROUND: In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, ...

Telaprevir for previously untreated chronic hepatitis C virus infection.

Jacobson I. M.
McHutchison J. G.
Dusheiko G.
Di Bisceglie A. M.
Reddy K. R.
Bzowej N. H.
Marcellin P.
Muir A. J.
Ferenci P.
Flisiak R.
George J.
Rizzetto M.
Shouval D.
Sola R.
Terg R. A.
Yoshida E. M.
Adda N.
Bengtsson L.
Sankoh A. J.
Kieffer T. L.
George S.
Kauffman R. S.
Zeuzem S.
ADVANCE Study Team: Gadano A.
Terg R.
Bell S.
Cheng W.
Crawford D.
Dore G.
George J.
MacDonald G.
Roberts S.
Ferenci P.
Gschwantler M.
Laferl H.
Maieron A.
Heathcote J.
Kaita K.
Myers R.
Sherman M.
Yoshida E.
Barange K.
Couzigou P.
Marcellin P.
Pawlotsky J. M.
Pol S.
Serfaty L.
Trépo C.
Zarski J. P.
Berg T.
Buggisch P.
Diepolder H.
Goeser T.
Mauss S.
Rasenack J.
Schmidt W.
Wedemeyer H.
Zeuzem S.
Baruch Y.
Ben Ari Z.
Maor Y.
Safadi R.
Shouval D.
Zuckerman E.
Colombo M.
Rizzetto M.
Baka Cwierz B.
Flisiak R.
Gladysz A.
Janczewska Kazek E.
Jablkowski M.
Krycka W.
Diago M.
Esteban Mur R.
Sanchez Tapias J.
Sola R.
Brown A.
Dusheiko G.
Fox R.
Afdhal N.
Arora S.
Bennett M.
Bernstein D.
Bloomer J.
Bochan M.
Bonkovsky H.
Brady C.
Brown R.
Bzowej N.
Cochran J.
Chasen R.
Davis G.
De Jesus E.
Di Bisceglie A.
Dienstag J.
Dieterich D.
Etzkorn K.
Everson G.
Fried M.
Freilich B.
Ghalib R.
Gitlin N.
Godofsky E.
Gordon S.
Hassanein T.
Jacobson I.
Javadi F.
Jonas M.
Kilby A.
Kwo P.
Lawitz E.
Lebovics E.
Lee W.
Luketic V.
Maillard M.
Monto A.
Morgan T.
Min A.
Murphy M.
Nelson D.
Northup P.
Nyberg L.
Pockros P.
Poordad F.
Poulos J.
Reddy R.
Rodriguez Torres M.
Satyanarayana R.
Schiff E.
Schwartz H.
Shaikh O.
Sheikh M.
Sherman K.
Smith J.
Strohecker J.
Sulkowski M.
Szabo G.
Te H.
Terrault N.
Tsai N.
Vargas H.
Vierling J.
Wruble L.
Younossi Z.
Zein N.
ANDREONE, PIETRO

January 2011

BACKGROUND: In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, ...

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.

Muir, Andrew,
Poordad, Fred,
Mchutchison, John,
Shiffman, Mitchell,
Berg, Thomas
Ferenci, Peter
Heathcote, E Jenny
Pawlotsky, Jean-Michel
Zeuzem, Stefan
Reesink, Henk,
Dusheiko, Geoffrey
Martin, Emily,
George, Shelley
Kauffman, Robert,
Adda, Nathalie

November 2011

International audienceRetreatment with peginterferon alpha and ribavirin (PR) offers a limited chanc...

Response-guided telaprevir combination treatment for hepatitis C virus infection.

Abstract

Extracted data

Response-guided telaprevir combination treatment for hepatitis C virus infection.

Abstract

Extracted data

Related items

Related items